Zheng, XL, Vesely, SK, Cataland, SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost 18:10 (2020), 2496–2502.
Cablivi (caplacizumab-yhdp). Summary of product characteristics. 2023, Ablynx NV.
Völker, LA, Kaufeld, J, Miesbach, W, et al. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv 4:13 (2020), 3085–3092.
Coppo, P, Bubenheim, M, Azoulay, E, et al. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood 137:6 (2021), 733–742.
Dutt, T, Shaw, RJ, Stubbs, M, et al. Real-world experience with caplacizumab in the management of acute TTP. Blood 137:13 (2021), 1731–1740.
Izquierdo, CP, Mingot-Castellano, ME, Fuentes, AEK, et al. Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura. Blood Adv 6:24 (2022), 6219–6227.
Agosti, P, De Leo, P, Capecchi, M, et al. Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan Thrombotic Thrombocytopenic Purpura Registry. Res Pract Thromb Haemost, 7(6), 2023, 102185.
Peyvandi, F, Scully, M, Kremer Hovinga, JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374:6 (2016), 511–522.
Scully, M, Cataland, SR, Peyvandi, F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380:4 (2019), 335–346.
Cablivi European Public Assessment Report (EPAR). https://www.ema.europa.eu/en/documents/overview/cablivi-epar-medicine-overview_en.pdf. (Accessed 1 November 2023)
FAMHP. Cablivi Use in Belgium (Federal Agency for Medicines and Health Products [FAMHP] Documentation). https://www.famhp.be/en/human_use/medicines/medicines/research_development/compassionate_use_medical_need/cablivi. (Accessed 1 November 2023)
Werion, A, Storms, P, Zizi, Y, et al. Epidemiology, outcomes, and complement gene variants in secondary thrombotic microangiopathies. Clin J Am Soc Nephrol 18:7 (2023), 881–891.
Cuker, A, Cataland, SR, Coppo, P, et al. Redefining outcomes in immune TTP: an International Working Group Consensus report. Blood 137:14 (2021), 1855–1861.
Scully, M, Cataland, S, Coppo, P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 15:2 (2017), 312–322.
Scully, M, de la Rubia, J, Pavenski, K, et al. Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: post-HERCULES study. J Thromb Haemost 20:12 (2022), 2810–2822.
